Skip to content
x.com· @ · X·· 2026-04-23Score60

HER2

Reading

Next-generation ADCs: payload innovation

T-DXd is already rewriting the first-line standard.

Body

MSK experts presented findings from their latest foundational and translational oncology research at #AACR26.

Here's a quick research roundup:

🔬 Highlights included treatment of early-stage #rectalcancer with protein inhibitors targeting HER2, alleviating the need for some patients to receive radiation and/or surgery. cc: @MichaelFoote & @AndreaCercek

🔬 Additional topics included the development of a personalized RNA vaccine for #pancreaticcancer, with almost 90% of responders still alive six years after treatment. cc: @TheVinodLab

🔬 And development of a framework to understand biomarkers and vulnerabilities during the early to late stages of transitions from #lungcancer-enabling adenomas to neuroendocrine lineage plasticity. cc: @jmchan88

Read more about these studies: https://t.co/KSoBfVaGnW

@AACR

Heat 31 · 23 likes · 1 reply · 7 reposts

Conference abstracts
CT011matched by 摘要号 CT011
Genomic HER2 amplification predicts for complete clinical response in a phase II study of induction tucatinib and trastuzumab combined with chemotherapy in locally advanced rectal adenocarcinoma

Michael B. Foote, Jinru Shia, Callahan Wilde, Marinela Capanu, Joanne Chou, Vetri Sudar Jayaprakasam, Marc Gollub, Miteshkumar Patel, Mina Ito, Leonard B. Saltz, Devika Rao, Neil Segal, Maliha Nusrat, Karuna Ganesh, Paul Romesser, Julio Garcia-Aguilar, Martin Weiser, Rona Yaeger, Luis A. Diaz, Andrea Cercek

Read the abstract →
CT012matched by 药名 zanidatamab
A phase 2 single-arm open-label trial evaluating zanidatamab in patients with early stage HER2 positive breast cancer: The NeoZanHER Study

Vicente Valero, Paula R. Pohlmann, Jason Mouabbi, Xuelin Huang, Wei Qiao, Heather R. Alonzo, Rashmi Krishna Murthy, Gaiane M. Rauch, Taiwo Adesoye, Cristina M. Checka, William F. Symmans, Dmitri Grachev, Flora Alajajyan, Adaeze Nwosu-Iheme, Amy Hassan, Miral Mahesh Patel, Sharon H. Giordano, Kelly Hunt, Debasish Tripathy, Funda Meric-Bernstam

Read the abstract →
CT045matched by 药名 sacituzumab
Initial clinical and translational results and selection of recommended phase 2 dose (RP2D) from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in metastatic triple-negative or HR+/HER2- breast cancer

Steven J Isakoff, Anastasia Martynova, Philippe L Bedard, Margaret E Gatti-Mays, Nathalie LeVasseur, Andreas Varkaris, William Randolph, Karunya Srinivasan, Shannon McCue, Zhenming Shun, Ke Liu, Zhen Su, Kevin Chin, Virginia Kaklamani, Kelly McCann, Erika Hamilton

Read the abstract →

Source: x.com · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org